Brief: Mithra Announces Improved Consolidated Topline Results From Donesta Phase 3 Studies

Mithra Pharmaceuticals SA

14/04/2022 06:45

April 14 (Reuters) - MITHRA PHARMACEUTICALS SA  MITRA.BR :
    * MITHRA ANNOUNCES IMPROVED CONSOLIDATED TOPLINE RESULTS
FROM
DONESTA® PHASE 3 STUDIES AND LAUNCH OF RECRUITMENT FOR THE
EXTENSION OF EUROPEAN STUDY
    * CONSOLIDATED ANALYSIS OF PHASE 3 TOP LINE DATA SHOWED EVEN
MORE
POSITIVE RESULTS THAN INITIALLY ANNOUNCED, WITH ALL FOUR
CO-PRIMARY ENDPOINTS MET
    * DONESTA® SAFETY PROFILE CONFIRMED BY INDEPENDENT DATA
SAFETY
MONITORING BOARD (DSMB), WHICH RECOMMENDED TO CONTINUE THE PHASE
III CLINICAL PROGRAM
    * LAUNCH OF THE RECRUITMENT OF THE ADDITIONAL 300 MENOPAUSAL
WOMEN
THANKS TO A SUCCESSFUL MITIGATION PLAN

Source text for Eikon:  ID:nNDL2N5bQR 
Further company coverage:  MITRA.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))